LIVE

BHC

Bausch Health Companies Inc.

BHC

NYSE·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $1.8B

$4.90

▲ +2.73%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$4.57 - $8.69

P/E

—

Fwd P/E

1.21

Beta

0.41

Div Yield

0.00%

Avg Vol

2.0M

Shares Out

373.5M

Mkt Cap

$1.8B

Price action

Price chart

Down 33.0% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Strong iconic brand portfolio including the globally recognized Bausch + Lomb name in vision care
  • Diversified product pipeline across high-demand therapeutic areas with recurring patient needs
  • Established international distribution network across Canada, Europe, Asia, and emerging markets
  • Integrated manufacturing and marketing capabilities providing operational efficiency and cost advantages
▼

Bear Case

1 risk

  • Low volatility (beta 0.4).

Growth

Turning profitable

Rising global demand for eye health and vision care solutions driven by aging populations and digital device usage

Value

Deep value opportunity - significant discount to Large Cap Pharma peers

Momentum

Weak

-10.8% over 3m

Quality

Excellent

Solid business

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Jul 29, 2026

“
Q2 26 RECAP

APR 29, 2026

Reported EPS of $0.78 vs $0.81 consensus (-3.7% surprise). Revenue of $2.5B vs $2.4B expected (+4.3%).

EPS miss
Rev beat +4.3%

EPS surprise · last 4Q

0 of 1 beats

Q2 26

-3.7%

Next: Jul 29, 2026

Revenue trend · last 8Q

—

—

—

—

+7%

+6%

+11%

+11%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$1.7B

$1.8B

$1.8B

$1.6B

$1.9B

$1.9B

$2.0B

$1.8B

Margins · last 8Q

Gross

61.2%

Operating

20.6%

Profit

-56.4%

View full earnings history →

Wall Street consensus

2 analysts · 0% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

0%

Hold

2

100%

Sell

0%

Median Price Target

—

Latest: RBC Capital · Apr 27, 2026

View full analyst page →

vs Industry

How BHC stacks vs Drug Manufacturers - Specialty & Generic

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.